건성안 환자에서 0.05% 싸이클로스포린 점안제의 순응도에 영향을 미치는 인자
Factors Affecting Compliance With 0.05% Cyclosporine Emulsion in Patients With Dry Eye Syndrome
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
목적: 건성안 환자에서 0.05% 싸이클로스포린 점안제의 순응도에 영향을 미치는 인자에 대해 알아보고자 하였다. 대상과 방법: 건성안으로 0.05% 싸이클로스포린 점안제를 사용 중인 148명을 대상으로, 처방된 횟수대로 안약을 사용한 빈도가 50%이상인 환자들을 순응도가 좋은 경우로 하여 두 군으로 분류하였다. 나이, 성별, 증상의 정도, 안약의 수, 사회경제적 상태, 부작용,상세한 설명 유무 등을 분석하여, 이 중 순응도와 관련 있는 인자를 조사하였다. 결과: 순응도가 좋은 군은 124명(83.8%), 순응도가 좋지 않은 군은 24명(16.2%)이었다. 다변량 로지스틱 회귀분석을 시행한 결과 증상이 심한 경우, 외래진료 간격이 긴 경우, 부작용이 있는 경우, 사회경제적 상태가 낮은 경우, 자세한 설명을 듣지 못한 경우 등이 순응도를 낮추는 인자로 분석되었다(P＜0.05). 나이, 성별, 사용한 안약의 수, 전신질환의 동반 유무 등의 인자들은 의미 없는 결과를 보였다. 결론: 건성안 환자에서 0.05% 싸이클로스포린 점안제 사용 시 상기 인자들을 충분히 고려하는 것이 치료 순응도를 높이는 데 도움이될 것으로 생각된다.
Abstract
Purpose: To evaluate the factors affecting compliance with the use of 0.05% cyclosporine emulsion in patients with dry eye syndrome. Methods: A total of 148 patients using 0.05% cyclosporine emulsion for dry eye were divided into two groups (compliant vs. non-compliant). The compliant group included the patients who used 0.05% cyclosporine emulsion more than 50% of frequency as they had been prescribed. We analyzed factors affecting compliance, including age, gender, severity of symptoms, side effects,use of topical steroid, socioeconomic status, associated systemic disease, number of eyedrops, visit interval, and detailed instruction about 0.05% cyclosporine emulsion. Results: The compliant group included 124 patients (83.8%), and the non-compliant group included 24 patients (16.2%). Multivariate analysis showed that the factors associated with low compliance were severe symptoms, longer visit interval, side effects, lower socioeconomic status, and poor detailed instruction (P＜0.05). In contrast, gender, associated systemic disease, and number of eyedrops did not affect the compliance for use of 0.05% cyclosporine emulsion. Conclusions: Special attention should be given to patients with the above risk factors to improve compliance with the use of 0.05% cyclosporine emulsion.
참고문헌 (24)
- "The definition and classification of dry eye disease", report of the definition and classification subcommittee of the International Dry Eye Workshop (2007), 통권 : 5, pp.75~92 (2007), Ocul Surf
- Sall K, "Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease", Ophthalmology, 107, pp.631~639 (2000)
- Stevenson D, "Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderateto-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group", Ophthalmology, 107, pp.967~974 (2000)
- Perry HD, "Topical 0.05% cyclosporine A in the treatment of dry eye", Expert Opin Phamacother, 5, pp.2099~2107 (2004)
- Trattler W, "Self-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveys", Clin Ther, 28, pp.1848~1856 (2006)
- Chiang TH, "Real-world utilization patterns of cyclosporine ophthalmic emulsion 0.05% within managed care", Can J Clin Pharmacol, 14, pp.240~245 (2007)
- Lam H, "Tear cytokine profiles in dysfunctional tear syndrome", Am J Ophthalmol, 147, pp.198~205 (2009)
- Chen JJ, "Corneal epithelial opacity in dysfunctional tear syndrome", Am J Ophthalmol, 148, pp.376~382 (2009)
- Krishnaiah S, "Smoking and its association with cataract: results of the Andhra Pradesh eye study from India", Invest Ophthalmol Vis Sci, 46, pp.58~65 (2005)
- Nussenblatt RB, "Cyclosporin: immunology, pharmacology and therapeutic use", Surv Ophthalmol, 31, pp.159~169 (1986)
- Hoffmann F, "Local treatment of corneal transplants in the human with cyclosporin A", Klin Monatsbl Augenheikd, 187, pp.92~96 (1985)
- Kiliç A, "Topical 2% cyclosporine A in preservative free artificial tears for the treatment of vernal keratoconjunctivitis", Can J Ophthalmol, 41, pp.693~698 (2006)
- Perry HD, "Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction", Cornea, 25, pp.171~175 (2006)
- Kunert KS, "Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine", Arch Ophthalmol, 120, pp.330~337 (2002)
- Stevenson D, "Efficacy and safety of cyclosporine A ophthalmic emulsion in the treatment of moderateto-severe dry eye disease: a dose-ranging, randomized trial. Cyclosporine A Phase 2 Study Group", Ophthalmology, 107, pp.967~974 (2000)
- Brignole F, "Flow cytometric analysis of inflammatory markers in KCS: 6-month treatment with topical cyclosporine A", Invest Ophthalmol Vis Sci, 42, pp.90~95 (2001)
- Turner K, "Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion", Cornea, 19, pp.492~496 (2000)
- Kunert KS, "Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes", Arch Ophthalmol, 118, pp.1489~1496 (2000)
- Holland EJ, "Topical cyclosporin A in the treatment of anterior segment inflammatory disease", Cornea, 12, pp.413~419 (1993)
- Barber LD, "Phase Ⅲ safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years", Am J Ophthalmol, 112, pp.1790~1794 (2005)
- Patel SC, "Compliance in patients prescribed eyedrops for glaucoma", Ophthalmic Surg, 26, pp.233~236 (1995)
- MacKean JM, "Compliance with treatment of patients with chronic open angle glaucoma", Br J Ophthalmol, 67, pp.46~49 (1983)
- Konstas AG, "Sardelli C. Compliance and viewpoint of glaucoma patients in Greece", Eye, 14, pp.752~756 (2000)
- Ahn DH, "Factors affecting compliance with prescribed eyedrops for glaucoma", J Korean Ophthalmol Soc, 39, pp.2145~2151 (1998)